DK1686999T3 - Pyrazolderivater som inhibitorer af receptortyrosinkinaser - Google Patents
Pyrazolderivater som inhibitorer af receptortyrosinkinaserInfo
- Publication number
- DK1686999T3 DK1686999T3 DK04798505T DK04798505T DK1686999T3 DK 1686999 T3 DK1686999 T3 DK 1686999T3 DK 04798505 T DK04798505 T DK 04798505T DK 04798505 T DK04798505 T DK 04798505T DK 1686999 T3 DK1686999 T3 DK 1686999T3
- Authority
- DK
- Denmark
- Prior art keywords
- inhibitors
- receptor tyrosine
- tyrosine kinases
- pyrazole derivatives
- pyrazole
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003217 pyrazoles Chemical class 0.000 title 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 title 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52058103P | 2003-11-17 | 2003-11-17 | |
US55621304P | 2004-03-25 | 2004-03-25 | |
PCT/GB2004/004784 WO2005049033A1 (fr) | 2003-11-17 | 2004-11-15 | Derives de pyrazole en tant qu'inhibiteurs de recepteur tyrosine kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1686999T3 true DK1686999T3 (da) | 2009-10-05 |
Family
ID=34623139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04798505T DK1686999T3 (da) | 2003-11-17 | 2004-11-15 | Pyrazolderivater som inhibitorer af receptortyrosinkinaser |
Country Status (26)
Country | Link |
---|---|
US (2) | US20070142413A1 (fr) |
EP (1) | EP1686999B1 (fr) |
JP (2) | JP4942486B2 (fr) |
KR (2) | KR20120094084A (fr) |
AR (1) | AR046779A1 (fr) |
AT (1) | ATE435017T1 (fr) |
AU (1) | AU2004290948B2 (fr) |
BR (1) | BRPI0416605A (fr) |
CA (1) | CA2545527C (fr) |
CY (1) | CY1110498T1 (fr) |
DE (1) | DE602004021844D1 (fr) |
DK (1) | DK1686999T3 (fr) |
ES (1) | ES2328042T3 (fr) |
HK (1) | HK1092723A1 (fr) |
HR (1) | HRP20090454T1 (fr) |
IL (1) | IL175487A (fr) |
MY (1) | MY141220A (fr) |
NO (1) | NO20062188L (fr) |
NZ (1) | NZ547938A (fr) |
PL (1) | PL1686999T3 (fr) |
PT (1) | PT1686999E (fr) |
RU (1) | RU2413727C2 (fr) |
SI (1) | SI1686999T1 (fr) |
TW (1) | TWI343383B (fr) |
UY (1) | UY28623A1 (fr) |
WO (1) | WO2005049033A1 (fr) |
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
PL377847A1 (pl) | 2003-01-14 | 2006-02-20 | Arena Pharmaceuticals Inc. | 1,2,3-Tripodstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie związanych z nim zaburzeń takich jak cukrzyca i hiperglikemia |
TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
US7793137B2 (en) | 2004-10-07 | 2010-09-07 | Cisco Technology, Inc. | Redundant power and data in a wired data telecommunincations network |
EP1812439B2 (fr) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Inhibiteurs de kinase |
AU2005322855B2 (en) | 2004-12-30 | 2012-09-20 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
PT2383268E (pt) * | 2005-02-04 | 2015-12-21 | Astrazeneca Ab | Derivados de pirazolilaminopiridina úteis como inibidores de quinase |
PT1853588E (pt) | 2005-02-16 | 2008-08-25 | Astrazeneca Ab | Compostos químicos |
US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
EP1877057A1 (fr) * | 2005-04-27 | 2008-01-16 | AstraZeneca AB | Utilisation des derives de la pyrazolyl-pyrimidine dans le traitement de la douleur |
EP1885369B1 (fr) | 2005-05-04 | 2015-09-23 | Evotec AG | Composes heterocycliques fusionnes, leurs compositions et leurs utilisations |
KR20080015409A (ko) * | 2005-05-16 | 2008-02-19 | 아스트라제네카 아베 | 티로신 키나제 억제제로서 유용한 피라졸릴아미노피리미딘 유도체 |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
EP1945631B8 (fr) * | 2005-10-28 | 2013-01-02 | AstraZeneca AB | Derives 4-(3-aminopyrazole)pyrimidine et leur utilisation en tant qu' inhibiteurs de tyrosine kinases dans le cadre d un traitement anticancereux |
CN101346371B (zh) * | 2005-10-28 | 2012-11-14 | 阿斯利康(瑞典)有限公司 | 癌症治疗中用作酪氨酸激酶抑制剂的4-(3-氨基吡唑)嘧啶衍生物 |
EP1951715B1 (fr) * | 2005-11-03 | 2013-09-04 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines utiles en tant qu'inhibiteurs de kinases |
US7514435B2 (en) | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
PT3184526T (pt) | 2005-12-13 | 2018-12-19 | Incyte Holdings Corp | Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus |
ES2395386T3 (es) | 2005-12-21 | 2013-02-12 | Abbott Laboratories | Compuestos antivirales |
AU2006330924B2 (en) * | 2005-12-21 | 2012-03-15 | Abbvie Inc. | Anti-viral compounds |
KR20090004976A (ko) * | 2006-04-19 | 2009-01-12 | 아스테라스 세이야쿠 가부시키가이샤 | 아졸카르복사미드 유도체 |
NZ563488A (en) * | 2006-04-19 | 2010-04-30 | Boehringer Ingelheim Int | Dihydrothienopyrimidines for the treatment of inflammatory diseases |
EP1847543A1 (fr) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidines pour le traitement de maladies inflammatoires |
EP2044063A1 (fr) * | 2006-06-30 | 2009-04-08 | Astra Zeneca AB | Dérivés de pyrimidine utiles dans le traitement du cancer |
WO2008005538A2 (fr) * | 2006-07-05 | 2008-01-10 | Exelixis, Inc. | Procédés d'utilisation de modulateurs de kinase igf1r et abl |
US9012162B2 (en) * | 2006-09-08 | 2015-04-21 | The Chancellor, Masters And Scholars Of The University Of Oxford | Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers |
JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
TW200823196A (en) * | 2006-11-01 | 2008-06-01 | Astrazeneca Ab | New use |
EP2094276A4 (fr) | 2006-12-20 | 2011-01-05 | Abbott Lab | Composés antiviraux |
US9187485B2 (en) | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
CN101679429A (zh) * | 2007-04-18 | 2010-03-24 | 阿斯利康(瑞典)有限公司 | 5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途 |
WO2008132502A1 (fr) * | 2007-04-25 | 2008-11-06 | Astrazeneca Ab | Pyrimidines substitués par pyrazolyle-amino et leur utilisation dans le traitement du cancer |
UA99459C2 (en) * | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
US20080312259A1 (en) | 2007-06-13 | 2008-12-18 | Incyte Corporation | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE |
WO2009013545A2 (fr) * | 2007-07-26 | 2009-01-29 | Astrazeneca Ab | Composés chimiques |
WO2009019518A1 (fr) * | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Composés de pyrimidine ayant un effet inhibiteur du fgfr |
EP2215092B1 (fr) | 2007-10-19 | 2012-01-25 | Boehringer Ingelheim International GmbH | Pipéridino-dihydrothiénopyrimidines substituées |
CA2702524A1 (fr) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Piperazino-dihydrothienopyrimidines substituees par un heterocycle |
WO2009050236A1 (fr) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Nouveaux dérivés de pipérazino-dihydrothiénopyrimidine |
WO2009054468A1 (fr) * | 2007-10-24 | 2009-04-30 | Astellas Pharma Inc. | Composé à base d'azolecarboxamide ou son sel |
WO2009056886A1 (fr) * | 2007-11-01 | 2009-05-07 | Astrazeneca Ab | Dérivés de pyrimidine et leur utilisation en tant que modulateurs de l'activité du fgfr |
EA020777B1 (ru) | 2007-11-16 | 2015-01-30 | Инсайт Корпорейшн | 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus |
CA2711865A1 (fr) | 2008-01-11 | 2009-07-16 | Astellas Pharma Inc. | Modele animal ayant a la fois une douleur dans les testicules ou des actions d'inconfort en relation aux testicules et une miction frequente |
CA2727073A1 (fr) * | 2008-06-11 | 2009-12-17 | Astrazeneca Ab | Derives tricycliques de 2,4-diamino-l,3,5-triazine utiles pour le traitement du cancer et de troubles myeloproliferatifs |
CN103965200B (zh) | 2008-09-22 | 2016-06-08 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物 |
RU2011116928A (ru) * | 2008-09-30 | 2012-11-20 | Астразенека Аб (Se) | Гетероциклические ингибиторы jак киназы |
LT3372605T (lt) | 2008-10-22 | 2022-02-10 | Array Biopharma, Inc. | Pakeistieji pirazolo[1,5-a]pirimidino junginiai, kaip trk kinazės inhibitoriai |
EP2210879A1 (fr) * | 2008-12-30 | 2010-07-28 | Bayer CropScience AG | Dérivés de pyrimidine et leur utilisation pour combattre la croissance indésirable de plantes |
CA2756871A1 (fr) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Composes heterocycliques substitues |
ES2527455T3 (es) * | 2009-05-14 | 2015-01-23 | The Chancellor, Masters And Scholars Of The University Of Oxford | Diagnóstico clínico de fibrosis/cirrosis hepática usando biomarcadores de proteínas plasmáticas humanas poco abundantes |
ES2487542T3 (es) | 2009-05-22 | 2014-08-21 | Incyte Corporation | Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus |
CN106967070A (zh) | 2009-05-22 | 2017-07-21 | 因塞特控股公司 | 作为jak抑制剂的化合物 |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
EP2464633A1 (fr) | 2009-08-14 | 2012-06-20 | Boehringer Ingelheim International GmbH | Préparation régiosélective de dérivés de 2-amino-5-trifluorométhylpyrimidine |
US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
TWI766281B (zh) | 2010-03-10 | 2022-06-01 | 美商英塞特控股公司 | 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物 |
KR102132405B1 (ko) | 2010-05-20 | 2020-07-09 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
DE102010025663A1 (de) * | 2010-06-30 | 2012-01-05 | Karl-Heinz Glüsenkamp | Neue beta-Aminoaldehyd-Derivate, Verfahren zu ihrer Herstellung und ihre chemische Verwendung als reaktive Intermediate |
BR112013008100A2 (pt) | 2010-09-22 | 2016-08-09 | Arena Pharm Inc | "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles." |
JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
BR112013029201B1 (pt) * | 2011-05-13 | 2022-08-09 | Array Biopharma Inc | Compostos de pirrolidinil ureia e pirrolidinil tioureia, seu processo de preparação, seu uso e composições farmacêuticas |
EA201490042A1 (ru) | 2011-06-20 | 2014-10-30 | Инсайт Корпорейшн | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
US8637537B2 (en) | 2011-08-25 | 2014-01-28 | Genentech, Inc. | Serine/threonine kinase inhibitors |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
BR112014015549A8 (pt) * | 2011-12-22 | 2017-07-04 | Hoffmann La Roche | composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção |
AU2013205306B2 (en) | 2012-03-16 | 2015-09-17 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物 |
SG11201503695XA (en) | 2012-11-15 | 2015-06-29 | Incyte Corp | Sustained-release dosage forms of ruxolitinib |
CN103012428A (zh) * | 2013-01-08 | 2013-04-03 | 中国药科大学 | 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途 |
HUE057262T2 (hu) | 2013-03-06 | 2022-04-28 | Incyte Holdings Corp | Eljárás és köztitermékek JAK inhibitor elõállítására |
US9655854B2 (en) | 2013-08-07 | 2017-05-23 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
RS64122B1 (sr) | 2014-11-16 | 2023-05-31 | Array Biopharma Inc | Kristalni oblik (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid hidrogensulfata |
AU2015369690B2 (en) | 2014-12-23 | 2019-01-17 | SMA Therapeutics Inc. | 3,5-diaminopyrazole kinase inhibitors |
AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
TN2017000502A1 (en) | 2015-06-01 | 2019-04-12 | Loxo Oncology Inc | Methods of diagnosing and treating cancer |
SI3310760T1 (sl) | 2015-06-22 | 2023-02-28 | Arena Pharmaceuticals, Inc. | Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1 |
LT3322706T (lt) | 2015-07-16 | 2021-03-10 | Array Biopharma, Inc. | Pakeistieji pirazolo[1,5-a]piridino junginiai, kaip ret kinazės inhibitoriai |
BR112018008357A2 (pt) | 2015-10-26 | 2018-11-27 | Array Biopharma Inc | mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
AU2017246554B2 (en) | 2016-04-04 | 2022-08-18 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
WO2017176744A1 (fr) | 2016-04-04 | 2017-10-12 | Loxo Oncology, Inc. | Méthodes de traitement de cancers pédiatriques |
HRP20230704T1 (hr) | 2016-05-18 | 2023-10-27 | Loxo Oncology, Inc. | Priprava (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida |
WO2018011681A1 (fr) | 2016-07-14 | 2018-01-18 | Pfizer Inc. | Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
WO2018136663A1 (fr) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Inhibiteurs de ret |
CA3049136C (fr) | 2017-01-18 | 2022-06-14 | Array Biopharma Inc. | Composes de pyrazolo[1,5-a]pyrazine substitues utilises en tant qu'inhibiteurs de la kinase ret |
KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
TW202410896A (zh) | 2017-10-10 | 2024-03-16 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
US20190247398A1 (en) | 2017-10-26 | 2019-08-15 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての置換ピラゾリル[4,3-c]ピリジン化合物 |
US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物 |
CN112105608B (zh) | 2018-01-30 | 2023-07-14 | 因赛特公司 | 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法 |
US20210023086A1 (en) | 2018-03-29 | 2021-01-28 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
AU2019245420A1 (en) | 2018-03-30 | 2020-11-12 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
AU2019314302A1 (en) | 2018-07-31 | 2021-01-28 | Loxo Oncology, Inc. | Spray-dried dispersions and formulations of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1H-pyrazole-4-carboxamide |
US11964988B2 (en) | 2018-09-10 | 2024-04-23 | Array Biopharma Inc. | Fused heterocyclic compounds as RET kinase inhibitors |
CN113490666A (zh) | 2018-12-19 | 2021-10-08 | 奥瑞生物药品公司 | 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物 |
US20220041579A1 (en) | 2018-12-19 | 2022-02-10 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of fgfr tyrosine kinases |
EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
EP4244910A1 (fr) | 2020-11-16 | 2023-09-20 | Credoxys GmbH c/o Institut for Applied Physics | Complexes de type cérium-éthylènediamine cétone et de type cérium-salen et leur utilisation dans l'électronique organique |
KR20230160350A (ko) * | 2021-03-24 | 2023-11-23 | 아토스 테라퓨틱스, 인크. | 키나제-관련 질환의 치료를 위한 소분자 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2400447C (fr) * | 2000-02-17 | 2008-04-22 | Amgen Inc. | Inhibiteurs de kinases |
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
-
2004
- 2004-11-12 MY MYPI20044727A patent/MY141220A/en unknown
- 2004-11-15 KR KR1020127017241A patent/KR20120094084A/ko not_active Application Discontinuation
- 2004-11-15 US US10/595,807 patent/US20070142413A1/en not_active Abandoned
- 2004-11-15 EP EP04798505A patent/EP1686999B1/fr active Active
- 2004-11-15 WO PCT/GB2004/004784 patent/WO2005049033A1/fr active Application Filing
- 2004-11-15 AU AU2004290948A patent/AU2004290948B2/en not_active Ceased
- 2004-11-15 PT PT04798505T patent/PT1686999E/pt unknown
- 2004-11-15 NZ NZ547938A patent/NZ547938A/en not_active IP Right Cessation
- 2004-11-15 AT AT04798505T patent/ATE435017T1/de active
- 2004-11-15 SI SI200431205T patent/SI1686999T1/sl unknown
- 2004-11-15 KR KR1020067011985A patent/KR101192939B1/ko not_active IP Right Cessation
- 2004-11-15 ES ES04798505T patent/ES2328042T3/es active Active
- 2004-11-15 DK DK04798505T patent/DK1686999T3/da active
- 2004-11-15 RU RU2006121337/04A patent/RU2413727C2/ru not_active IP Right Cessation
- 2004-11-15 JP JP2006540576A patent/JP4942486B2/ja not_active Expired - Fee Related
- 2004-11-15 CA CA2545527A patent/CA2545527C/fr not_active Expired - Fee Related
- 2004-11-15 BR BRPI0416605-1A patent/BRPI0416605A/pt not_active IP Right Cessation
- 2004-11-15 PL PL04798505T patent/PL1686999T3/pl unknown
- 2004-11-15 DE DE602004021844T patent/DE602004021844D1/de active Active
- 2004-11-17 TW TW093135262A patent/TWI343383B/zh not_active IP Right Cessation
- 2004-11-17 AR ARP040104237A patent/AR046779A1/es not_active Application Discontinuation
- 2004-11-17 UY UY28623A patent/UY28623A1/es not_active Application Discontinuation
-
2006
- 2006-05-08 IL IL175487A patent/IL175487A/en not_active IP Right Cessation
- 2006-05-15 NO NO20062188A patent/NO20062188L/no not_active Application Discontinuation
- 2006-12-11 HK HK06113587.6A patent/HK1092723A1/xx not_active IP Right Cessation
-
2009
- 2009-08-21 HR HR20090454T patent/HRP20090454T1/hr unknown
- 2009-09-16 CY CY20091100953T patent/CY1110498T1/el unknown
-
2010
- 2010-02-25 US US12/712,659 patent/US20100152219A1/en not_active Abandoned
-
2011
- 2011-11-07 JP JP2011243454A patent/JP2012082198A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1686999T3 (da) | Pyrazolderivater som inhibitorer af receptortyrosinkinaser | |
DK1667991T3 (da) | Quinazolinderivater som tyrosinkinaseinhibitorer | |
DK1532138T3 (da) | Inhibitorer af tyrosinkinaser | |
DK1786799T3 (da) | Hidtil ukendte phenylaminopyrimidinderivater som inhibitorer af bcr-abl-kinase | |
DK1562589T3 (da) | Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser | |
DK1811998T3 (da) | Triazoler anvendelige som inhibitorer af proteinkinaser | |
DK1463506T3 (da) | Substituerede quinazolin-derivater som inhibitorer af aurora-kinaser | |
DK1664043T3 (da) | Sammensætninger egnede som inhibitorer af proteinkinaser | |
DK1585749T3 (da) | Diazepinoindol-derivater som kinaseinhibitorer | |
DK1761505T3 (da) | Pyrimidin-urinstof-derivater som kinaseinhibitorer | |
DE602005025733D1 (de) | Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase | |
DK2261223T3 (da) | Pyrimidinderivater anvendt som PI-3-kinasehæmmere | |
DK2120932T3 (da) | Indazolderivater som kinasehæmmere til behandling af kræft | |
NO20091423L (no) | Pyrimidinderivater og deres anvendelse som kinaseinhibitorer | |
DK1556375T3 (da) | Flavonderivater som inhibitorer af cyklinafhængige kinaser | |
DK1778686T3 (da) | Triazolopyridinylsulfanylderivater som P38 MAP kinase-inhibitorer | |
DK1711481T3 (da) | Fremgangsmåde til fremstilling af 2-aminothiazol-5-aromatiske carboxamider som kinaseinhibitorer | |
DK1763517T3 (da) | Pyrimidinderivater som 11beta-HSD1-inhibitorer | |
IL173200A0 (en) | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors | |
DK1945631T3 (da) | 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer | |
DK1981875T3 (da) | Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase | |
DK1805164T3 (da) | 6-(pyridinyl)-4-pyrimidonderivater som inhibitorer af TAU 1 oroteinkinase | |
DK1740569T3 (da) | Imidazol-derivater som TAFla-inhibitorer | |
DK1711177T3 (da) | 1H-thieno-2,3-c-pyrazolderivater, der er egnede som kinase-I-inhibitorer | |
ATE393159T1 (de) | Heterobicyclische pyrazolderivate als kinaseinhibitoren |